Karyopharm director awarded 15,508 RSUs

Karyopharm Therapeutics Inc. director Barry E. Greene reported an equity compensation grant.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. director Barry E. Greene reported an equity compensation grant. He received 15,508 restricted stock units (RSUs) of common stock at no cash cost under the company’s 2022 Equity Incentive Plan, as amended.

The RSUs convert into common stock on a one-for-one basis and vest 100% on May 21, 2027. Delivery of shares is deferred until the earlier of Greene’s separation from service or a change-in-control event. After this award, he holds 16,415 shares of common stock directly. All amounts reflect Karyopharm’s one-for-fifteen reverse stock split effected on February 25, 2025.

Insider Trade Summary

Grant/Award: 15,508 shares

Grant/Award 1 txn

Insider Greene Barry E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,508	$0.00	$0.00

Holdings After Transaction: Common Stock — 16,415 shares (Direct)

Footnotes (2)

1. F1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
2. F2. Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

Key Figures

RSU grant size: 15,508 RSUs Shares held after transaction: 16,415 shares Reverse stock split ratio: one-for-fifteen +1 more

4 metrics

RSU grant size 15,508 RSUs Equity award to director on May 21, 2026

Shares held after transaction 16,415 shares Director’s direct common stock holdings following RSU grant

Reverse stock split ratio one-for-fifteen Reverse stock split effective February 25, 2025

RSU vesting date May 21, 2027 100% vesting date for awarded RSUs

Key Terms

restricted stock units ("RSUs"), 2022 Equity Incentive Plan, one-for fifteen reverse stock split, change-in-control event

4 terms

restricted stock units ("RSUs") financial

"Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2022 Equity Incentive Plan financial

"pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended."

one-for fifteen reverse stock split financial

"reflect the one-for fifteen reverse stock split effected by Karyopharm"

change-in-control event financial

"earlier of (a) the date of the director's separation from service... and (b) a change-in-control event."

FAQ

What insider transaction did KPTI director Barry E. Greene report?

Barry E. Greene reported receiving 15,508 restricted stock units (RSUs) of Karyopharm Therapeutics common stock as an equity award. The RSUs were granted at no cash cost and come under the company’s 2022 Equity Incentive Plan, as amended.

How many RSUs did KPTI grant to Barry Greene and when do they vest?

Barry Greene received 15,508 restricted stock units (RSUs) that vest 100% on May 21, 2027. Once vested, each RSU converts into one share of Karyopharm Therapeutics common stock, subject to the plan’s delivery and deferral conditions.

When will Barry Greene receive the KPTI shares underlying his RSUs?

Shares underlying Barry Greene’s RSUs are delivered at the earlier of his separation from service or a change-in-control event. Although the RSUs vest on May 21, 2027, actual share delivery is deferred until one of those triggering events occurs.

How many KPTI shares does Barry Greene hold after this Form 4 transaction?

Following this award, Barry Greene directly holds 16,415 shares of Karyopharm Therapeutics common stock. This total reflects the impact of the company’s one-for-fifteen reverse stock split that was effected on February 25, 2025, as noted in the disclosure footnote.

How did Karyopharm’s reverse stock split affect the figures in this Form 4?

All share amounts in this Form 4 reflect Karyopharm’s one-for-fifteen reverse stock split effective February 25, 2025. The reported 15,508 RSUs and 16,415 shares following the transaction are already adjusted to account for that reverse split ratio.

What plan governs Barry Greene’s RSU award from Karyopharm Therapeutics (KPTI)?

Barry Greene’s 15,508 RSU award was granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. The plan provides for equity-based compensation, including RSUs that convert into common stock on a one-for-one basis upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greene Barry E

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		15,508(1)	A	$0	16,415(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.

2. Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

	/s/ Nancy Smith, Attorney-in-Fact for Barry Greene	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)